ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ANNX vs COLL // NET PROFIT MARGIN

Annexon Inc. (NASDAQ) VS. Collegium Pharmaceutical Inc. (NASDAQ) • 15-METRIC TALLY: ANNX 0 — COLL 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANNX VS. COLL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ANNX COLL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 59.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 85.00% -120.00 COLL /roic <GO>
EV/EBITDA & P/E Valuation — 3.0x — TIE /valuation <GO>
Free Cash Flow Yield -24.53% — — TIE /fcf-yield <GO>
Operating Margin — 23.00% — TIE /operating-margins <GO>
Net Profit Margin ACTIVE — 8.10% — TIE /net-margins <GO>
Revenue Growth (YoY) — 23.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 1.27 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 COLL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.4 56.9 -4.48 COLL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 10.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $760.2M $782.3M -$22.1M COLL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ANNX REV COLL REV ANNX GROSS % COLL GROSS % ANNX FCF COLL FCF
FY 2025 $0 $780.6M — 59.3% -$186.5M $327.6M
FY 2024 $0 $631.4M — 59.8% -$118.0M $203.3M
FY 2023 $0 $566.8M — — -$121.1M $274.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANNX // BETA —
COLL // BETA —